Want to see HK:2135 full AI Analyst Report?
2135 Stock Chart & Stats
HK$0.17
<HK$0.01(0.99%)
At close: 4:00 PM EST
HK$0.17
<HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.20
Previous CloseN/A
Volume240.00K
Average Volume (3M)289.64K
Market Cap
HK$53.48M
Enterprise ValueHK$56.10M
Total Cash (Recent Filing)HK$57.82M
Total Debt (Recent Filing)HK$59.18M
Price to Earnings (P/E)26.8
Beta0.76
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding557,077,330
10 Day Avg. Volume121,000
30 Day Avg. Volume289,644
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Free Cash Flow Strength2025's strong operating cash flow (~34.7M) and free cash flow (~32.0M) materially improve liquidity and internal funding capacity. Durable FCF provides flexibility for debt service, reinvestment, or strategic initiatives and reduces near-term refinancing risk.
Margin Recovery And ProfitabilityMargins rebounded sharply in 2025 (gross ~41%, EBITDA ~15%) and the company returned to small net profitability, implying structural cost control or pricing improvements. Sustained margin improvement supports operating leverage and longer-term earnings durability if maintained.
Manageable LeverageDebt-to-equity near 0.55 in 2025 suggests a moderate and manageable balance-sheet profile. This degree of leverage reduces immediate solvency pressure, preserving capacity to invest or withstand shocks while the company works to convert recent profitability into higher returns.
Bears Say
Thin Net MarginA net margin of roughly 1% after multiple loss-making years means profits are highly sensitive to small revenue drops or cost rises. The prior multi-year losses indicate the company has not yet firmly re-established durable, cyclical-proof profitability.
Volatile Cash ConversionHistorical volatility in operating cash flow—including negative cash flow in 2021–2022—undermines confidence that 2025's FCF is sustainable. Inconsistent cash conversion complicates planning, raises refinancing uncertainty, and weakens the reliability of internal funding.
Declining Revenue TrendA negative revenue growth rate (~-4.86% year-over-year) signals demand weakness or pricing pressure. Falling top-line constrains the scalability of fixed-cost leverage, making it harder to sustain recent margin and profit improvements without renewed revenue growth.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.09 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$53.48M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Aug 21, 2026 which is in 32 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Medicskin Holdings Ltd.
―
Saint Bella Inc.
―